Hypermatrix factors for string and membrane junctions

The adjoint representations of the Lie algebras of the classical groups SU(n), SO(n), and Sp(n) are, respectively, tensor, antisymmetric, and symmetric products of two vector spaces, and hence are matrix representations. We consider the analogous products of three vector spaces and study when they appear as summands in Lie algebra decompositions. The Z3-grading of the exceptional Lie algebras provide such summands and provides representations of classical groups on hypermatrices. The main natural application is a formal study of three-junctions of strings and membranes. Generalizations are also considered.Comment: 25 pages, 4 figures, presentation improved, minor correction

Complementarity of the Maldacena and Karch-Randall Pictures

We perform a one-loop test of the holographic interpretation of the Karch-Randall model, whereby a massive graviton appears on an AdS_4 brane in an AdS_5 bulk. Within the AdS/CFT framework, we examine the quantum corrections to the graviton propagator on the brane, and demonstrate that they induce a graviton mass in exact agreement with the Karch-Randall result. Interestingly enough, at one loop order, the spin 0, spin 1/2 and spin 1 loops contribute to the dynamically generated (mass)^2 in the same 1: 3: 12 ratio as enters the Weyl anomaly and the 1/r^3 corrections to the Newtonian gravitational potential.Comment: 20 pages, Revtex 3, Discussion on the absence of a scalar ghost clarified; Additional details on the computation give

Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry

Background and purpose: Prospectively collected data comparing the safety and effectiveness of individual non-vitamin K antagonists (NOACs) are lacking. Our objective was to directly compare the effectiveness and safety of NOACs in patients with newly diagnosed atrial fibrillation (AF). Methods: In GLORIA-AF, a large, prospective, global registry program, consecutive patients with newly diagnosed AF were followed for 3 years. The comparative analyses for (1) dabigatran vs rivaroxaban or apixaban and (2) rivaroxaban vs apixaban were performed on propensity score (PS)-matched patient sets. Proportional hazards regression was used to estimate hazard ratios (HRs) for outcomes of interest. Results: The GLORIA-AF Phase III registry enrolled 21,300 patients between January 2014 and December 2016. Of these, 3839 were prescribed dabigatran, 4015 rivaroxaban and 4505 apixaban, with median ages of 71.0, 71.0, and 73.0 years, respectively. In the PS-matched set, the adjusted HRs and 95% confidence intervals (CIs) for dabigatran vs rivaroxaban were, for stroke: 1.27 (0.79–2.03), major bleeding 0.59 (0.40–0.88), myocardial infarction 0.68 (0.40–1.16), and all-cause death 0.86 (0.67–1.10). For the comparison of dabigatran vs apixaban, in the PS-matched set, the adjusted HRs were, for stroke 1.16 (0.76–1.78), myocardial infarction 0.84 (0.48–1.46), major bleeding 0.98 (0.63–1.52) and all-cause death 1.01 (0.79–1.29). For the comparison of rivaroxaban vs apixaban, in the PS-matched set, the adjusted HRs were, for stroke 0.78 (0.52–1.19), myocardial infarction 0.96 (0.63–1.45), major bleeding 1.54 (1.14–2.08), and all-cause death 0.97 (0.80–1.19). Conclusions: Patients treated with dabigatran had a 41% lower risk of major bleeding compared with rivaroxaban, but similar risks of stroke, MI, and death. Relative to apixaban, patients treated with dabigatran had similar risks of stroke, major bleeding, MI, and death. Rivaroxaban relative to apixaban had increased risk for major bleeding, but similar risks for stroke, MI, and death. Registration: URL: https://www.clinicaltrials.gov. Unique identifiers: NCT01468701, NCT01671007. Date of registration: September 2013

Anticoagulant selection in relation to the SAMe-TT2R2 score in patients with atrial fibrillation. the GLORIA-AF registry

Aim: The SAMe-TT2R2 score helps identify patients with atrial fibrillation (AF) likely to have poor anticoagulation control during anticoagulation with vitamin K antagonists (VKA) and those with scores >2 might be better managed with a target-specific oral anticoagulant (NOAC). We hypothesized that in clinical practice, VKAs may be prescribed less frequently to patients with AF and SAMe-TT2R2 scores >2 than to patients with lower scores. Methods and results: We analyzed the Phase III dataset of the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF), a large, global, prospective global registry of patients with newly diagnosed AF and ≥1 stroke risk factor. We compared baseline clinical characteristics and antithrombotic prescriptions to determine the probability of the VKA prescription among anticoagulated patients with the baseline SAMe-TT2R2 score >2 and ≤ 2. Among 17,465 anticoagulated patients with AF, 4,828 (27.6%) patients were prescribed VKA and 12,637 (72.4%) patients an NOAC: 11,884 (68.0%) patients had SAMe-TT2R2 scores 0-2 and 5,581 (32.0%) patients had scores >2. The proportion of patients prescribed VKA was 28.0% among patients with SAMe-TT2R2 scores >2 and 27.5% in those with scores ≤2. Conclusions: The lack of a clear association between the SAMe-TT2R2 score and anticoagulant selection may be attributed to the relative efficacy and safety profiles between NOACs and VKAs as well as to the absence of trial evidence that an SAMe-TT2R2-guided strategy for the selection of the type of anticoagulation in NVAF patients has an impact on clinical outcomes of efficacy and safety. The latter hypothesis is currently being tested in a randomized controlled trial. Clinical trial registration: URL: https://www.clinicaltrials.gov//Unique identifier: NCT01937377, NCT01468701, and NCT01671007

WHO global research priorities for antimicrobial resistance in human health

The WHO research agenda for antimicrobial resistance (AMR) in human health has identified 40 research priorities to be addressed by the year 2030. These priorities focus on bacterial and fungal pathogens of crucial importance in addressing AMR, including drug-resistant pathogens causing tuberculosis. These research priorities encompass the entire people-centred journey, covering prevention, diagnosis, and treatment of antimicrobial-resistant infections, in addition to addressing the overarching knowledge gaps in AMR epidemiology, burden and drivers, policies and regulations, and awareness and education. The research priorities were identified through a multistage process, starting with a comprehensive scoping review of knowledge gaps, with expert inputs gathered through a survey and open call. The priority setting involved a rigorous modified Child Health and Nutrition Research Initiative approach, ensuring global representation and applicability of the findings. The ultimate goal of this research agenda is to encourage research and investment in the generation of evidence to better understand AMR dynamics and facilitate policy translation for reducing the burden and consequences of AMR

Chemical composition and antimicrobial activity of fatty acid methyl ester of <i>Quercus leucotrichophora</i> fruits

<p>Natural fats and dietary oils are chief source of fatty acids and are well known to have antimicrobial activities against various microbes. The chemical composition and antimicrobial activities of fatty acids from fruits of white Oak (<i>Quercus leucotrichophora</i>) are yet unexplored and therefore the present study for the first time determines the fatty acid composition, and the antibacterial and antifungal activities of fatty acid methyl esters (FAME) of the white Oak plant found along the Himalayan region of Uttarakhand, India. The GCMS analysis revealed the presence of higher amount of saturated fatty acids than unsaturated fatty acids. FAME extract of fruits of <i>Q. leucotrichophora</i> demonstrated better antibacterial activity against Gram-positive bacteria than the Gram-negative bacteria. The present studies clearly establish the potential of the fruits of <i>Q. leucotrichophora</i> for use in soap, cosmetics and pharmaceutical industries.</p